Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1981 October; 68(4): 1053–1064.
PMCID: PMC370893

Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine.


This study was undertaken to investigate the effect of exogenous sulfhydryl compound administration on the toxicity of doxorubicin in mice. Pretreatment of CDF1 mice with a pharmacologic dose (2,000 mg/kg) of n-acetyl-l-cysteine 1 h before doxorubicin (20 mg/kg, i.p.) decreased lethality from 100% (n = 44) to 37.7% (n = 53), P less than 0.001. Variation in the timing and dose of n-acetylcysteine significantly diminished its protective activity. Pretreatment with n-acetylcysteine also significantly reduced long-term mortality in animals receiving multiple doses of doxorubicin; 10 wk after the third of three doxorubicin doses (5 mg/kg, i.p.) administered at 2-wk intervals, survival in the n-acetylcysteine pretreated group was 51.4% (n = 35) compared with 16.7% (n = 30) for animals receiving saline before doxorubicin, P less than 0.01. In this experiment, n-acetylcysteine pretreatment also diminished doxorubicin-related losses in total body weight and heart wet weight by 55.2% (P less than 0.05), and 60.9% (P less than 0.02), respectively, compared with animals pretreated with saline. N-acetylcysteine pretreatment also ablated electron microscopic evidence of doxorubicin cardiomyopathy without alleviating morphological features of its toxic effects on the liver or small intestinal mucosa. The cardioprotective action of n-acetylcysteine may be partially explained by the 429 +/- 60% increase in cardiac nonprotein sulfhydryl content (P less than 0.01) that was measured one hour after n-acetylcysteine administration; nonprotein sulfhydryl concentration in the liver at the same time was insignificantly different from control levels. Treatment with n-acetylcysteine also increased the nonprotein sulfhydryl content of P388 leukemia cells nearly threefold; however, it did not after the chemotherapeutic activity of doxorubicin against this murine tumor. Whereas n-acetylcysteine blocked doxorubicin cardiac toxicity, it did not affect the uptake or metabolism of doxorubicin in the heart or liver. These results suggest that the concentration of free sulfhydryl groups in the heart may play a role in the development of doxorubicin cardiac toxicity and that augmenting cardiac nonprotein sulfhydryl group content with n-acetylcysteine may provide a means to enhance the chemotherapeutic index of doxorubicin.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Carter SK. Adriamycin-a review. J Natl Cancer Inst. 1975 Dec;55(6):1265–1274. [PubMed]
  • Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978 Feb;88(2):168–175. [PubMed]
  • Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med. 1978 Nov;65(5):823–832. [PubMed]
  • Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977 Jul 8;197(4299):165–167. [PubMed]
  • Bachur NR, Gordon SL, Gee MV. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res. 1978 Jun;38(6):1745–1750. [PubMed]
  • Komiyama T, Oki T, Inui T. A proposed reaction mechanism for the enzymatic reductive cleavage of glycosidic bond in anthracycline antibiotics. J Antibiot (Tokyo) 1979 Nov;32(11):1219–1222. [PubMed]
  • Thayer WS. Adriamycin stimulated superoxide formation in submitochondrial particles. Chem Biol Interact. 1977 Dec;19(3):265–278. [PubMed]
  • Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep. 1978 Jun;62(6):955–961. [PubMed]
  • Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest. 1980 Jan;65(1):128–135. [PMC free article] [PubMed]
  • Burton GM, Henderson CA, Balcerzak SP, Sagone AL., Jr Effect of adriamycin on the metabolism of heart slices. Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1287–1289. [PubMed]
  • Doroshow JH, Locker GY, Baldinger J, Myers CE. The effect of doxorubicin on hepatic and cardiac glutathione. Res Commun Chem Pathol Pharmacol. 1979 Nov;26(2):285–295. [PubMed]
  • Wang YM, Madanat FF, Kimball JC, Gleiser CA, Ali MK, Kaufman MW, van Eys J. Effect of vitamin E against adriamycin-induced toxicity in rabbits. Cancer Res. 1980 Apr;40(4):1022–1027. [PubMed]
  • Kosower EM. A role for glutathione in muscle contraction. Experientia. 1970;26(7):760–761. [PubMed]
  • Galvin MJ, Lefer AM. Salutary effects of cysteine on cardiogenic shock in cats. Am J Physiol. 1978 Dec;235(6):H657–H663. [PubMed]
  • Armstrong DA, Buchanan JD. Reactions of O-.2, H2O2 and other oxidants with sulfhydryl enzymes. Photochem Photobiol. 1978 Oct-Nov;28(4-5):743–755. [PubMed]
  • Gardner HW, Weisleder D. Addition of N-acetylcysteine to linoleic acid hydroperoxide. Lipids. 1976 Feb;11(2):127–134. [PubMed]
  • Gardner HW, Kleiman R, Weisleder D, Inglett GE. Cysteine adds to liquid hydroperoxide. Lipids. 1977 Aug;12(8):655–660. [PubMed]
  • Sonneveld P. Effect of alpha-tocopherol on the cardiotoxicity of adriamycin in the rat. Cancer Treat Rep. 1978 Jul;62(7):1033–1036. [PubMed]
  • Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem. 1968 Oct 24;25(1):192–205. [PubMed]
  • Bradner WT, Schurig JE, Huftalen JB, Doyle GJ. Evaluation of antitumor drug side effects in small animals. Cancer Chemother Pharmacol. 1980;4(2):95–101. [PubMed]
  • Schwartz HS. A fluorometric assay for daunomycin and adriamycin in animal tissues. Biochem Med. 1973 Jun;7(3):396–404. [PubMed]
  • Benjamin RS, Riggs CE, Jr, Bachur NR. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res. 1977 May;37(5):1416–1420. [PubMed]
  • Chan KK, Wong CD. Quantitative thin-layer chromatography: thin-film fluorescence scanning analysis of adriamycin and metabolites in tissue. J Chromatogr. 1979 Apr 21;172:343–349. [PubMed]
  • Van Vleet JF, Greenwood LA, Ferrans VJ. Pathologic features of adriamycin toxicosis in young pigs: nonskeletal lesions. Am J Vet Res. 1979 Nov;40(11):1537–1552. [PubMed]
  • Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed]
  • Casagrande JT, Pike MC. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics. 1978 Sep;34(3):483–486. [PubMed]
  • Ball CR. Estimation and identification of thiols in rat spleen after cysteine or glutathione treatment: relevance to protection against nitrogen mustards. Biochem Pharmacol. 1966 Jul;15(7):809–816. [PubMed]
  • Lorber A, Chang CC, Masuoka D, Meacham I. Effect of thiols in biological systems on protein sulfhydryl content. Biochem Pharmacol. 1970 May;19(5):1551–1560. [PubMed]
  • Bertazzoli C, Bellini O, Magrini U, Tosana MG. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1877–1883. [PubMed]
  • Prothero J. Heart weight as a function of body weight in mammals. Growth. 1979 Sep;43(3):139–150. [PubMed]
  • Mimnaugh EG, Siddik ZH, Drew R, Sikic BI, Gram TE. The effects of alpha-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice. Toxicol Appl Pharmacol. 1979 Jun 15;49(1):119–126. [PubMed]
  • Rosenoff SH, Brooks E, Bostick F, Young RC. Alterations in DNA synthesis in cardiac tissue induced by adriamycin in vivo-relationship to fatal toxicity. Biochem Pharmacol. 1975 Oct 15;24(20):1898–1901. [PubMed]
  • Sheffner AL, Medler EM, Bailey KR, Gallo DG, Mueller AJ, Sarett HP. Metabolic studies with acetylcysteine. Biochem Pharmacol. 1966 Oct;15(10):1523–1535. [PubMed]
  • Freiman JA, Chalmers TC, Smith H, Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med. 1978 Sep 28;299(13):690–694. [PubMed]
  • Freeman RW, MacDonald JS, Olson RD, Boerth RC, Oates JA, Harbison RD. Effect of sulfhydryl-containing compounds on the antitumor effects of adriamycin. Toxicol Appl Pharmacol. 1980 Jun 15;54(1):168–175. [PubMed]
  • Chou T, Hill EJ, Bartle E, Woolley K, LeQuire V, Olson W, Roelofs R, Park JH. Beneficial effects of penicillamine treatment on hereditary avian muscular dystrophy. J Clin Invest. 1975 Oct;56(4):842–849. [PMC free article] [PubMed]
  • Patnode R, Bartle E, Hill EJ, LeQuire V, Park JH. Enzymological studies on hereditary avian muscular dystrophy. J Biol Chem. 1976 Jul 25;251(14):4468–4475. [PubMed]
  • Griffith OW, Meister A. Glutathione: interorgan translocation, turnover, and metabolism. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5606–5610. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation